We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.59B
AUM Growth
+$1.11B
Cap. Flow
-$1.32B
Cap. Flow %
-13.72%
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$117M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$109M
3
BSX icon
Boston Scientific
BSX
+$71.4M
4
PBLS
Parabilis Medicines Inc
PBLS
+$52M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$36.3M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$141M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$80.4M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$79.8M
5
EHAB
Enhabit
EHAB
+$66.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.76%
2 Miscellaneous 16.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$83.6M 0.87%
13,569,000
– –
LNTH icon
27
Lantheus
LNTH
$6.56B
$83.5M 0.87%
752,999
-75,000
-9% -$6.99M
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.8B
$82.6M 0.86%
3,779,900
– –
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$12.6B
$76.3M 0.8%
1,332,836
+481,280
+57% +$26.4M
PFE icon
30
Pfizer
PFE
$160B
$73.2M 0.76%
3,040,000
– –
INDV icon
31
Indivior Pharmaceuticals
INDV
$4.17B
$67.7M 0.71%
1,648,895
-1,448,895
-47% -$52.6M
BIO icon
32
Bio-Rad Laboratories Class A
BIO
$10.4B
$66.4M 0.69%
226,070
– –
SPRY icon
33
ARS Pharmaceuticals
SPRY
$600M
$60.1M 0.63%
7,503,812
– –
STOK icon
34
Stoke Therapeutics
STOK
$2.1B
$59.7M 0.62%
1,823,500
– –
GPCR icon
35
Structure Therapeutics
GPCR
$3.51B
$58.3M 0.61%
1,086,000
+318,007
+41% +$14.1M
NVST icon
36
Envista
NVST
$4.41B
$58.2M 0.61%
2,210,100
– –
INSP icon
37
Inspire Medical Systems
INSP
$1.76B
$57.9M 0.6%
1,296,862
-1,406,376
-52% -$66.7M
CDNA icon
38
CareDx
CDNA
$2.71B
$56.9M 0.59%
1,997,618
-193,382
-9% -$4.21M
BSX icon
39
Boston Scientific
BSX
$67.6B
$56.1M 0.59%
+1,315,000
New +$71.4M
BLTE
40
Belite Bio
BLTE
$6.32B
$55M 0.57%
357,199
+53,186
+17% +$8.15M
PBLS
41
Parabilis Medicines Inc
PBLS
$4.85B
$51.5M 0.54%
+1,880,704
New +$52M
CERT icon
42
Certara
CERT
$1.28B
$49.2M 0.51%
7,512,928
-295,677
-4% -$1.67M
IRON icon
43
Disc Medicine
IRON
$3.17B
$48.1M 0.5%
657,000
– –
BBOT
44
BridgeBio Oncology
BBOT
$736M
$37.2M 0.39%
4,885,446
– –
TYRA icon
45
Tyra Biosciences
TYRA
$1.56B
$32.5M 0.34%
1,017,000
+468,000
+85% +$15.5M
MNPR icon
46
Monopar Therapeutics
MNPR
$765M
$30M 0.31%
323,745
– –
SION
47
Sionna Therapeutics
SION
$274M
$30M 0.31%
680,916
-289,674
-30% -$11.6M
AVLN
48
Avalyn Pharma
AVLN
$1.62B
$24.1M 0.25%
+731,000
New +$21.1M
FHTX icon
49
Foghorn Therapeutics
FHTX
$369M
$21.4M 0.22%
4,394,367
– –
BBNX
50
Beta Bionics
BBNX
$879M
$20.7M 0.22%
1,324,000
– –
1
2
3 4

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q2 2026 Portfolio in Review

As of Q2 2026, Deerfield Management held 94 positions worth $9.59B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.

  • Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
  • Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
  • Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
  • Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
  • Deerfield Management's ten largest holdings make up 53% of its $9.59B portfolio in Q2 2026.
  • Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
  • Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.59B.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.